Exosomal LINC00323 accelerates angiogenesis through activating the MAPK and JAK-STAT pathways by stabilizing CDC5L in NSCLC Authors: Bin Ke, Hai Zhong, Xiaofei Chen, Lijun He, Chenxin Yan, Jianjun Li, Lin Shi Published: 2026 ABSTRACT BackgroundNon-small cell lung cancer (NSCLC) stands as a predominant contributor to cancer-related mortality, with angiogenesis serving a pivotal role in the advancement of the disease. The upregulation of LINC00323 in NSCLC has been identified; however, its function in facilitating NSCLC progression remains ambiguous. This investigation delves into the implications of LINC00323 on cellular proliferation, angiogenesis, and associated pathways in NSCLC, emphasizing its regulation of CDC5L stability and its presence within exosomes.MethodsThe expression of LINC00323 was scrutinized in NSCLC tissues and cells through RT-qPCR and FISH techniques. The influence of LINC00323 and exosomes derived from NSCLC cells with modified LINC00323 expression on cellular proliferation and angiogenesis was evaluated in A549 and H358 cell lines. Co-culture with HUVECs was employed to assess endothelial functionality. RNA pull-down assays and proteomic analyses identified CDC5L as a downstream target of LINC00323. The activation of MAPK and JAK-STAT pathways was investigated via Western blotting.ResultsThe results indicated that LINC00323 was significantly upregulated in NSCLC tissues, correlating with a poorer prognosis and heightened angiogenesis. Overexpression of LINC00323 facilitated cellular proliferation and angiogenesis, while its knockdown impeded these processes. Moreover, exosomes containing LINC00323 from NSCLC cells stimulated angiogenesis and preserved endothelial barrier integrity in HUVECs. LINC00323 was shown to directly interact with and stabilize CDC5L. Functional complementation experiments demonstrated that the knockdown of CDC5L counteracted the effects of LINC00323 overexpression on cellular proliferation, angiogenesis, and the MAPK/JAK-STAT pathways in vitro. In vivo studies revealed that LINC00323 knockdown in A549 xenografts led to reductions in tumor size, angiogenesis, and the MAPK and JAK-STAT pathways, with CDC5L overexpression mitigating these effects.ConclusionsLINC00323 within exosomes accelerates the progression of NSCLC and activates the MAPK and JAK-STAT pathways by stabilizing CDC5L. These findings underscore LINC00323 as a potential therapeutic target for NSCLC, particularly in its modulation of the angiogenesis.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1007/s13402-026-01248-9. Introduction Lung cancer continues to be the most common malignant neoplasm worldwide and has the highest mortality rate [1]. Non-small cell lung cancer (NSCLC) accounts for approximately 80% of all lung cancer cases [2]. Despite progress in early diagnosis and treatment strategies, the prognosis for advanced-stage NSCLC patients remains poor, primarily due to metastasis, angiogenesis and drug resistance [3]. Angiogenesis, the process of forming new blood vessels, is critical to NSCLC progression, as it supplies tumors with essential nutrients and oxygen, thereby supporting their growth and promoting metastasis [4]. Although the VEGF and MAPK/ERK pathways are well established as central regulators of angiogenesis [5], the precise molecular mechanisms and upstream factors involved in NSCLC have not been fully elucidated. Long noncoding RNAs (lncRNAs), which were once considered simple transcriptional byproducts, have now emerged as key players in cancer biology [6, 7]. These molecules can regulate gene expression, cell proliferation, migration, invasion, angiogenesis, etc [8, 9]. Among these lncRNAs, LINC00323 has recently gained attention due to its upregulation in several cancers, including breast, gastric, and colorectal cancer (CRC), where higher expression correlates with poorer prognosis and more aggressive disease behavior [10–12]. Recent reviews highlight that exosomal lncRNAs play important roles in cancer progression, particularly in regulating angiogenesis, metastasis, and tumor immunity, and may serve as therapeutic targets or biomarkers [13]. In NSCLC, exosomal lncRNAs have been shown to affect proliferation, invasion, metastasis, and angiogenesis, indicating their clinical relevance [14]. LINC00323 has been linked to the regulation of critical pathways, such as the PI3K/AKT, Wnt/β-catenin, and mTOR pathways [15], which are related to cell proliferation, migration, and angiogenesis [16, 17]. However, its specific role in NSCLC, particularly in the modulation of angiogenesis, remains largely unexplored. Given the crucial role of angiogenesis, understanding regulatory molecules such as LINC00323 could provide novel insights into therapeutic strategies aimed at inhibiting tumor progression. In our previous proteomic analysis of NSCLC tissues, LINC00323-overexpressing cells were compared with control cells in three different cell lines, and cell division cycle 5-like (CDC5L) was identified as a pivotal factor in NSCLC progression mediated by LINC00323. CDC5L plays a role in controlling the G2/M transition of the cell cycle, ensuring proper cell division [18]. High levels of CDC5L expression are associated with poor prognosis in various cancers, indicating that CDC5L is a promising target for therapeutic intervention [18, 19]. For example, CDC5L can promote tumor progression in gastric cancer (GC) by regulating the MAPK pathway [20]. Its overexpression is linked to resistance to chemotherapy in multiple myeloma [21]. Additionally, CDC5L interacts with major pathways, such as the MAPK/ERK and JAK/STAT pathways [20], which regulate cell proliferation, survival, and angiogenesis. However, the mechanisms governing CDC5L expression and its modulation in NSCLC, particularly in relation to LINC00323, are not fully understood. We hypothesize that LINC00323 modulates CDC5L stability and function, thereby promoting angiogenesis and driving tumor progression in NSCLC. In addition, we propose that LINC00323 stabilizes CDC5L through direct interaction, preventing its degradation and facilitating the activation of downstream pathways such as the MAPK/ERK and JAK/STAT pathways. These pathways were screened through proteomic analysis. This process is expected to increase the angiogenic potential of NSCLC tumors. Exosomes, which are small vesicles secreted by cells, have gained attention in cancer research because of their pivotal role in mediating intercellular communication [22]. These vesicles carry various molecular components, such as proteins, lipids, and RNAs, that can affect numerous aspects of tumor biology, including angiogenesis and metastasis [23–25]. Recent studies suggest that exosomal long noncoding RNAs (lncRNAs) can influence endothelial cell function and potentially contribute to blood vessel formation within tumors [26, 27]. Considering the involvement of LINC00323 in tumor progression, we hypothesize that exosomal LINC00323 may play a role in angiogenesis by transferring key molecular signals, including CDC5L, to endothelial cells in the TME. However, this hypothesis has yet to be confirmed by direct evidence, and further studies are necessary to fully understand the role of LINC00323 in NSCLC. This study was designed to explore the molecular mechanisms through which LINC00323 influences the stability of CDC5L and its subsequent impact on angiogenesis and tumor progression. Additionally, we will verify the potential role of exosomal LINC00323 in regulating endothelial cell function and angiogenesis in NSCLC via a combination of in vitro and in vivo models, including assays for cell proliferation, angiogenesis, exosome isolation, and protein analysis. The results of this study may position LINC00323 as a promising therapeutic target for NSCLC, suggesting novel strategies to inhibit tumor growth and angiogenesis. Furthermore, this research provides deeper insights into the molecular interactions between LINC00323 and CDC5L, as well as the contribution of exosomal LINC00323 to modulating the tumor microenvironment, potentially leading to more effective treatment strategies for NSCLC patients. Results LINC00323 upregulation correlates with angiogenesis and poor prognosis in NSCLC We initially observed that LINC00323 expression was upregulated in NSCLC tumor tissues relative to PCT, as determined by RT-qPCR and FISH assays (Fig. 1A and B). Tumor samples displayed a markedly higher fluorescence intensity of LINC00323, confirming its elevated expression in these tissues (Fig. 1C). Additionally, survival analysis exhibited that high LINC00323 expression was strongly associated with reduced overall survival rates in NSCLC patients (Fig. 1D). Regarding angiogenesis, IHC staining demonstrated a marked upregulation of VEGFA and CD31 expression in tumor tissues, both of which are established markers of angiogenesis (Fig. 1E and G). Furthermore, MVD analysis also revealed a noticeable increase in MVD within the tumor tissues (Fig. 1H). A correlation analysis between LINC00323 expression and angiogenesis markers revealed a strong positive association with VEGFA (r = 0.6827, Fig. 1I), CD31 (r = 0.6418, Fig. 1J), and MVD (r = 0.6275, Fig. 1K). These results imply that LINC00323 may play a role in angiogenesis and could act as a potential prognostic marker in NSCLC. Fig. 1LINC00323 expression and its association with angiogenesis in NSCLC. (A) Relative expression of LINC00323 in PCT and tumor tissues of NSCLC patients, as determined by RT‒qPCR. (B) FISH of LINC00323 in tumor and PCT tissues. Scale bar = 100 μm. (C) Fluorescence intensity of LINC00323 expression in tumor versus PCT tissues. (D) Kaplan‒Meier survival analysis of NSCLC patients with high vs. low LINC00323 expression (P < 0.0001). (E) IHC staining for VEGFA and CD31 in PCT and tumor tissues. Scale bar = 100 μm. (F) VEGFA expression, as assessed by the H score. (G) CD31 expression, as assessed by the H score. (H) MVD analysis of PCT and tumor tissues. MVD was quantified by counting CD31-positive microvessels in five randomly selected high-power fields per section, and the average was used for analysis. (I) Correlation between LINC00323 expression and the VEGFA H score. (J) Correlation between LINC00323 expression and the CD31 H-score. (K) Correlation between LINC00323 expression and the MVD. ***P < 0.001 LINC00323 expression and its association with angiogenesis in NSCLC. (A) Relative expression of LINC00323 in PCT and tumor tissues of NSCLC patients, as determined by RT‒qPCR. (B) FISH of LINC00323 in tumor and PCT tissues. Scale bar = 100 μm. (C) Fluorescence intensity of LINC00323 expression in tumor versus PCT tissues. (D) Kaplan‒Meier survival analysis of NSCLC patients with high vs. low LINC00323 expression (P < 0.0001). (E) IHC staining for VEGFA and CD31 in PCT and tumor tissues. Scale bar = 100 μm. (F) VEGFA expression, as assessed by the H score. (G) CD31 expression, as assessed by the H score. (H) MVD analysis of PCT and tumor tissues. MVD was quantified by counting CD31-positive microvessels in five randomly selected high-power fields per section, and the average was used for analysis. (I) Correlation between LINC00323 expression and the VEGFA H score. (J) Correlation between LINC00323 expression and the CD31 H-score. (K) Correlation between LINC00323 expression and the MVD. ***P < 0.001 LINC00323 upregulation promotes proliferation and vascular-like structure formation in A549 and H358 cells We then assessed LINC00323 expression in several cell lines, observing higher expression in A549, HCC827, H1650, and H358 cells than that in normal BEAS-2B cells (Fig. 2A). Based on the highest expression of LINC00323 in A549 and the lowest in H358, we selected these two cell lines for further experimentation. Following the overexpression (OE-323) and knockdown (sh-323) of LINC00323 in A549 and H358 cells (Fig. 2B), we investigated its impact on cell proliferation in A549 and H358 cells. The CCK-8 results demonstrated that LINC00323 overexpression in A549 and H358 cells enhanced cell proliferation, with a marked increase in cell viability across all time points (Fig. 2C). In contrast, knockdown of LINC00323 in A549 and H358 cells led to a notable reduction in cell proliferation, further confirming its role in promoting cell growth. These findings in A549 and H358 cells were corroborated by EdU assays (Fig. 2D and E). To further assess the role of LINC00323 in angiogenesis, we conducted tube formation assays using matrigel in A549 and H358 cells. LINC00323 overexpression led to more extensive tube-like structures in A549 and H358 cells, while LINC00323 knockdown reduced tube formation (Fig. 2F and G). Furthermore, quantification of junctions, a key indicator of tube formation, revealed more junctions in A549 and H358 cells overexpressing LINC00323 and fewer junctions in knockdown cells (Fig. 2H). Together, these results demonstrate that LINC00323 plays a critical role in promoting both cell proliferation and angiogenesis in A549 and H358 NSCLC cells. Fig. 2LINC00323 regulates proliferation and vascular-like structure formation in A549 and H358 cells. (A) Relative expression of LINC00323 in BEAS-2B, A549, HCC827, H1650, and H358 cells was analyzed via RT‒qPCR. (B) Relative expression of LINC00323 was confirmed by RT‒qPCR in A549 and H358 cells following overexpression (OE-323) or knockdown (sh-323) of LINC00323. (C) Cell proliferation was assessed by CCK-8 assays at 24, 48, and 72 h in A549 and H358 cells treated with OE-323 or sh-323. (D) Representative images from EdU incorporation assays in LINC00323-overexpressing or LINC00323-silenced A549 and H358 cells. Scale bar = 100 μm. (E) EdU-positive cells. (F) Tube formation in Matrigel was assessed in A549 and H358 cells, showing tube-like structures under different LINC00323 expression conditions. Scale bar = 200 μm. (G) Relative tube length. (H) Junctions formed by A549 and H358 cells in the tube formation assay, reflecting angiogenic activity following LINC00323 modulation. ***P < 0.001 LINC00323 regulates proliferation and vascular-like structure formation in A549 and H358 cells. (A) Relative expression of LINC00323 in BEAS-2B, A549, HCC827, H1650, and H358 cells was analyzed via RT‒qPCR. (B) Relative expression of LINC00323 was confirmed by RT‒qPCR in A549 and H358 cells following overexpression (OE-323) or knockdown (sh-323) of LINC00323. (C) Cell proliferation was assessed by CCK-8 assays at 24, 48, and 72 h in A549 and H358 cells treated with OE-323 or sh-323. (D) Representative images from EdU incorporation assays in LINC00323-overexpressing or LINC00323-silenced A549 and H358 cells. Scale bar = 100 μm. (E) EdU-positive cells. (F) Tube formation in Matrigel was assessed in A549 and H358 cells, showing tube-like structures under different LINC00323 expression conditions. Scale bar = 200 μm. (G) Relative tube length. (H) Junctions formed by A549 and H358 cells in the tube formation assay, reflecting angiogenic activity following LINC00323 modulation. ***P < 0.001 LINC00323 overexpression in A549 and H358 cells modulates HUVEC tube formation and barrier function via co-culture To further examine the effect of LINC00323 on angiogenesis of HUVECs, HUVECs were co-cultured with A549 and H358 cells overexpressing or silenced for LINC00323 (Fig. 3A). After co-culture with differently treated A549 and H358 cells, LINC00323 expression in HUVECs increased in the overexpression group and decreased in the knockdown group (Fig. 3B). The CCK-8 assay demonstrated that LINC00323 overexpression in A549 and H358 cells enhanced HUVEC viability, while knockdown reduced it (Fig. 3C). In the tube formation assay, HUVECs co-cultured with LINC00323-overexpressing A549 and H358 cells formed longer and more branched tubes in Matrigel, whereas knockdown cells produced fewer and shorter tubes (Fig. 3D and E). Quantification of junctions confirmed these results, with more junctions in the overexpression group and fewer in the knockdown group (Fig. 3F). Furthermore, TEER measurements showed that LINC00323 overexpression improved endothelial barrier integrity, while knockdown impaired it (Fig. 3G). These findings suggest that NSCLC-derived LINC00323 promotes HUVEC tube formation and endothelial barrier function, highlighting its critical role in vascular formation and endothelial integrity. Fig. 3Effect of NSCLC-derived LINC00323 on HUVEC angiogenesis and barrier function. (A) Schematic diagram of the co-culture system with A549 and H358 cells (OE-323 or sh-323) and HUVECs. (B) LINC00323 expression in HUVECs after co-culture with treated A549 and H358 cells. (C) HUVEC proliferation assessed by CCK-8. (D) HUVEC tube formation in Matrigel after co-culture with OE-323 or sh-323 A549 and H358 cells. Scale bar = 200 μm. (E) Quantification of tube length. (F) Quantification of junctions formed in the tube formation assay. (G) TEER of HUVEC monolayers after co-culture with transfected A549 and H358 cells. **P < 0.01 Effect of NSCLC-derived LINC00323 on HUVEC angiogenesis and barrier function. (A) Schematic diagram of the co-culture system with A549 and H358 cells (OE-323 or sh-323) and HUVECs. (B) LINC00323 expression in HUVECs after co-culture with treated A549 and H358 cells. (C) HUVEC proliferation assessed by CCK-8. (D) HUVEC tube formation in Matrigel after co-culture with OE-323 or sh-323 A549 and H358 cells. Scale bar = 200 μm. (E) Quantification of tube length. (F) Quantification of junctions formed in the tube formation assay. (G) TEER of HUVEC monolayers after co-culture with transfected A549 and H358 cells. **P < 0.01 Exosomal LINC00323 from NSCLC cells promotes HUVEC tube formation and endothelial barrier function To identify the role of LINC00323 in exosomes on HUVECs, exosomes were isolated from A549 and H358 cells treated with Triton X-100 and RNase. RT-qPCR confirmed the presence of LINC00323 in exosomes, and Triton X-100 plus RNase treatment reduced its levels, whereas RNase alone had no effect (Figs. 4A). A schematic of the experimental procedure shows that A549 cells were transfected with LINC00323 overexpression (OE) or knockdown (sh) plasmids. Exosomes were then isolated via ultracentrifugation and characterized using TEM, NTA, and Western blot, followed by co-culture with HUVECs (Fig. 4B). TEM revealed the characteristic cup-shaped morphology of exosomes (Figs. 4C and S1A), and NTA confirmed the size distribution (Fig. 4D). Western blot detected exosomal markers CD63, CD81, and CD9 (Fig. 4E). RT-qPCR showed that exosomes from LINC00323-overexpressing NSCLC cells had higher LINC00323 levels, whereas knockdown exosomes had lower levels compared with controls (Figs. 4F and S1B). HUVECs efficiently took up exosomes as shown by confocal IF (Figs. 4G and S1C). RT-qPCR of HUVECs revealed higher LINC00323 expression after co-culture with overexpressing exosomes and decreased expression with knockdown exosomes (Figs. 4H and S1D). CCK-8 assays demonstrated that HUVEC proliferation increased with overexpressing exosomes and decreased with knockdown exosomes (Figs. 4I and S1E). In tube formation assays, HUVECs co-cultured with overexpressing exosomes formed longer and more branched tubes in Matrigel, whereas knockdown exosomes resulted in shorter and fewer tubes (Fig. 4J and K, and S1F, S1G). Quantification of junctions confirmed these effects, with more junctions in the overexpression group (Figs. 4L and S1H). TEER measurements indicated that exosomes from overexpressing NSCLC cells improved endothelial barrier integrity, while knockdown exosomes disrupted it (Figs. 4M and S1I). Together, these results emphasize that exosomal LINC00323 from NSCLC cells enhances HUVEC tube formation and endothelial barrier function. Fig. 4Exosomal LINC00323 from A549 cells promotes angiogenesis and endothelial function in HUVECs. (A) RT‒qPCR analysis of LINC00323 expression in A549 and H358 cells treated with Triton X-100 and RNase. (B) Schematic overview of the experimental setup. (C) TEM image of exosomes isolated from A549 cells. (D) NTA. (E) Western blot detection of exosomal markers (CD63, CD81, and CD9) in exosomes from A549 cells. (F) RT‒qPCR analysis of LINC00323 expression in exosomes derived from A549 cells with LINC00323 overexpression or knockdown. (G) Confocal images of HUVECs cocultured with exosomes from A549 cells. (H) Relative LINC00323 expression in HUVECs after coculture with exosomes from A549 cells with LINC00323 overexpression or knockdown. (I) HUVEC viability was assessed via a CCK-8 assay after exposure to exosomes from LINC00323-overexpressing or -knockdown A549 cells. (J) Tube formation by HUVECs cultured with exosomes from LINC00323-modified A549 cells in Matrigel. Scale bar = 200 μm. (K) Relative tube length formed by HUVECs after coculture with the exosomes. (L) Junctions formed by HUVECs in the tube formation assay after coculture with exosomes. (M) TEER measurements of HUVEC monolayers cocultured with exosomes. **P < 0.01, ***P < 0.001 Exosomal LINC00323 from A549 cells promotes angiogenesis and endothelial function in HUVECs. (A) RT‒qPCR analysis of LINC00323 expression in A549 and H358 cells treated with Triton X-100 and RNase. (B) Schematic overview of the experimental setup. (C) TEM image of exosomes isolated from A549 cells. (D) NTA. (E) Western blot detection of exosomal markers (CD63, CD81, and CD9) in exosomes from A549 cells. (F) RT‒qPCR analysis of LINC00323 expression in exosomes derived from A549 cells with LINC00323 overexpression or knockdown. (G) Confocal images of HUVECs cocultured with exosomes from A549 cells. (H) Relative LINC00323 expression in HUVECs after coculture with exosomes from A549 cells with LINC00323 overexpression or knockdown. (I) HUVEC viability was assessed via a CCK-8 assay after exposure to exosomes from LINC00323-overexpressing or -knockdown A549 cells. (J) Tube formation by HUVECs cultured with exosomes from LINC00323-modified A549 cells in Matrigel. Scale bar = 200 μm. (K) Relative tube length formed by HUVECs after coculture with the exosomes. (L) Junctions formed by HUVECs in the tube formation assay after coculture with exosomes. (M) TEER measurements of HUVEC monolayers cocultured with exosomes. **P < 0.01, ***P < 0.001 LINC00323 regulates HUVEC proliferation, angiogenesis, and endothelial integrity Then, LINC00323 was overexpressed (OE-323) and knocked down (sh-323) in HUVECs to assess its functional impact (Fig. 5A). RT-qPCR confirmed a marked increase in LINC00323 expression in the overexpression group and a decrease in the knockdown group compared to controls (Fig. 5B). In terms of cell viability of HUVECs, CCK-8 assays showed a increase in the overexpression group, while the knockdown group exhibited a marked reduction in cell viability (Fig. 5C). In the angiogenesis assay, LINC00323 overexpression led to the formation of more extensive tube-like structures in Matrigel, while the knockdown group formed fewer and shorter tubes in HUVECs (Fig. 5D and E). Junction formation quantification supported these findings, showing more junctions in the overexpression group and fewer in the knockdown group (Fig. 5F). Finally, TEER measurements demonstrated that LINC00323 overexpression improved endothelial barrier function, while its knockdown led to a reduction in barrier integrity (Fig. 5G). Together, these results indicate that LINC00323 also plays a role in promoting HUVEC proliferation, angiogenesis, and enhancing endothelial barrier function. Fig. 5Effect of LINC00323 overexpression and knockdown on HUVEC proliferation, angiogenesis, and TEER. (A) Schematic overview of the experimental setup. HUVECs were transfected with LINC00323 overexpression (OE-323) or knockdown (sh-323) plasmids. (B) RT-qPCR analysis of LINC00323 expression in HUVECs after transfection. (C) Cell viability of HUVECs was assessed using CCK-8 assay after transfection with LINC00323-modified plasmids. (D) tube formation by HUVECs in Matrigel after transfection with LINC00323-modified plasmids. (E) Relative tube length formed by HUVECs. (F) Quantification of the number of junctions formed by HUVECs in the angiogenesis assay. (G) TEER measurements of HUVEC monolayers after transfection with LINC00323 overexpression or knockdown plasmids. Scale bar = 200 μm. **P < 0.01, ***P < 0.001 Effect of LINC00323 overexpression and knockdown on HUVEC proliferation, angiogenesis, and TEER. (A) Schematic overview of the experimental setup. HUVECs were transfected with LINC00323 overexpression (OE-323) or knockdown (sh-323) plasmids. (B) RT-qPCR analysis of LINC00323 expression in HUVECs after transfection. (C) Cell viability of HUVECs was assessed using CCK-8 assay after transfection with LINC00323-modified plasmids. (D) tube formation by HUVECs in Matrigel after transfection with LINC00323-modified plasmids. (E) Relative tube length formed by HUVECs. (F) Quantification of the number of junctions formed by HUVECs in the angiogenesis assay. (G) TEER measurements of HUVEC monolayers after transfection with LINC00323 overexpression or knockdown plasmids. Scale bar = 200 μm. **P < 0.01, ***P < 0.001 LINC00323 promotes angiogenesis through regulates CDC5L mediated MAPK and JAK-STAT3 pathways To verify the impact of LINC00323 on protein expression, proteomics analysis was conducted on A549, H358, and HUVEC cells after LINC00323 overexpression (OE-323). The analysis revealed notable changes in protein profiles between LINC00323-overexpressed and control cells, as shown by the heatmap (Fig. 6A). A Venn diagram illustrated the overlap of DEPs across the three cell lines (Fig. 6B). GSEA of these proteins highlighted the angiogenesis, MAPK, and JAK-STAT pathways as affected by LINC00323 (Fig. 6C). RNA pull-down combined with proteomics data suggested that CDC5L is a potential target of LINC00323 (Fig. 6D and E, and Table S1). Western blot analysis proved that CDC5L expression was notably higher in the three cells with LINC00323 overexpression and lower in those with LINC00323 knockdown (Fig. 6F). Additionally, p-JAK1, p-STAT3, p-ERK1/2, and p-p38 expressions were upregulated in LINC00323 overexpressing cells and downregulated in LINC00323 knockdown cells (Fig. 6G). These data signified that LINC00323 might promote angiogenesis through regulates CDC5L mediated MAPK and JAK-STAT3 pathways. Fig. 6LINC00323 regulates angiogenesis and the MAPK and JAK-STAT pathways and targets CDC5L in A549, H358, and HUVECs. (A) Heatmap of DEPs in A549, H358, and HUVECs after LINC00323 overexpression, as determined by proteomics analysis. (B) Venn diagram showing the overlap of DEPs between A549, H358, and HUVECs. (C) GSEA of the DEPs revealed that the angiogenesis, MAPK, and JAK-STAT pathways were regulated by LINC00323 overexpression. (D) Venn diagram showing the overlap of proteins identified by LINC00323 RNA pull-down. (E) Venn diagram showing the overlap of the proteomics data and RNA pull-down results. (F) Western blot analysis of CDC5L expression in A549, H358, and HUVECs after overexpression (OE-323) or knockdown (sh-323) of LINC00323. (G) Western blot analysis of A549, H358, and HUVECs after LINC00323 overexpression or knockdown LINC00323 regulates angiogenesis and the MAPK and JAK-STAT pathways and targets CDC5L in A549, H358, and HUVECs. (A) Heatmap of DEPs in A549, H358, and HUVECs after LINC00323 overexpression, as determined by proteomics analysis. (B) Venn diagram showing the overlap of DEPs between A549, H358, and HUVECs. (C) GSEA of the DEPs revealed that the angiogenesis, MAPK, and JAK-STAT pathways were regulated by LINC00323 overexpression. (D) Venn diagram showing the overlap of proteins identified by LINC00323 RNA pull-down. (E) Venn diagram showing the overlap of the proteomics data and RNA pull-down results. (F) Western blot analysis of CDC5L expression in A549, H358, and HUVECs after overexpression (OE-323) or knockdown (sh-323) of LINC00323. (G) Western blot analysis of A549, H358, and HUVECs after LINC00323 overexpression or knockdown LINC00323 directly regulates CDC5L stability by suppressing its ubiquitination To examine the interaction between LINC00323 and CDC5L, RNA pull-down assays were conducted using LINC00323 sense and antisense strands in A549, H358, and HUVEC cells. The results confirmed that LINC00323 directly interacts with CDC5L, with the interaction being observed in cells transfected with both the sense strands of LINC00323 (Fig. 7A). Further analysis of CDC5L protein degradation was conducted by treating cells with a protein synthesis inhibitor (CHX). Western blot analysis at time points (0, 4, 8, and 12 h) showed a faster degradation of CDC5L in LINC00323 knockdown cells relative to control cells, indicating that LINC00323 plays a role in stabilizing CDC5L (Fig. 7B and C). Besides, the data revealed that treatment with MG132 resulted in the restoration of CDC5L protein levels in the LINC00323 knockdown group (Fig. 7D and E). Then, we further identified the specific region of LINC00323 that interacts with CDC5L using RNA pull-down assay with different fragments of LINC00323. And the results pinpointed the binding region critical for the interaction (Fig. 7F). Furthermore, the interaction between LINC00323 and CDC5L, as well as the effect on CDC5L ubiquitination, was further analyzed using Co-IP assays. The results demonstrated that LINC00323 knockdown led to increased CDC5L ubiquitination in A549, H358, and HUVEC cells (Fig. 7G and H). Thus, LINC00323 plays a critical role in regulating CDC5L stability and ubiquitination. Fig. 7LINC00323 interacts with CDC5L and regulates its stability and ubiquitination. (A) The interaction between LINC00323 and CDC5L was identified via an RNA pull-down assay with LINC00323 sense and antisense strands in A549, H358, and HUVECs. (B) Western blot analysis of CDC5L levels in A549, H358, and HUVECs after treatment with 50 µg/mL CHX for 0, 4, 8, and 12 h to inhibit protein synthesis. (C) CDC5L protein degradation, ***P < 0.001. (D) Western blot analysis of CDC5L expression in A549, H358, and HUVECs after treatment with 25 mM MG132 to assess CDC5L protein degradation. (E) CDC5L protein levels in A549, H358, and HUVECs after MG132 treatment; **P < 0.01 vs. the control group; ##P < 0.01 vs. the MG132 group. (F) RNA pull-down assay identifying the binding region of LINC00323 that interacts with CDC5L. (G) Co-IP analysis of CDC5L and ubiquitin detection revealed the interaction between LINC00323 and CDC5L and the change in CDC5L ubiquitination following LINC00323 knockdown. (H) Quantification of CDC5L ubiquitination levels in A549, H358, and HUVECs after LINC00323 knockdown, ***P < 0.001 LINC00323 interacts with CDC5L and regulates its stability and ubiquitination. (A) The interaction between LINC00323 and CDC5L was identified via an RNA pull-down assay with LINC00323 sense and antisense strands in A549, H358, and HUVECs. (B) Western blot analysis of CDC5L levels in A549, H358, and HUVECs after treatment with 50 µg/mL CHX for 0, 4, 8, and 12 h to inhibit protein synthesis. (C) CDC5L protein degradation, ***P < 0.001. (D) Western blot analysis of CDC5L expression in A549, H358, and HUVECs after treatment with 25 mM MG132 to assess CDC5L protein degradation. (E) CDC5L protein levels in A549, H358, and HUVECs after MG132 treatment; **P < 0.01 vs. the control group; ##P < 0.01 vs. the MG132 group. (F) RNA pull-down assay identifying the binding region of LINC00323 that interacts with CDC5L. (G) Co-IP analysis of CDC5L and ubiquitin detection revealed the interaction between LINC00323 and CDC5L and the change in CDC5L ubiquitination following LINC00323 knockdown. (H) Quantification of CDC5L ubiquitination levels in A549, H358, and HUVECs after LINC00323 knockdown, ***P < 0.001 The correlation between CDC5L expression and angiogenesis in NSCLC tissues To identify the expression of CDC5L in NSCLC tissues and its association with LINC00323 and angiogenesis. Western blot and IHC assay were conducted on paired tumor and PCT tissues from NSCLC patients. Western blot results revealed higher CDC5L protein expression in tumor tissues than that in PCT tissues (Fig. 8A and B). IHC staining further confirmed that CDC5L expression was notably increased in tumor tissues (Fig. 8C and D). Besides, we observed a positive correlation between LINC00323 expression and CDC5L levels (Fig. 8E). Furthermore, CDC5L expression correlated with angiogenesis markers CD31 and VEGFA, as the IHC H-scores of CDC5L positively correlated with those of CD31 and VEGFA (Fig. 8F and G). CDC5L expression was also positively associated with MVD (Fig. 8H). These data uncover a correlation between CDC5L expression and LINC00323, as well as key angiogenesis markers in NSCLC tissues. Fig. 8Expression of CDC5L in NSCLC tissues and its correlation with LINC00323, CD31, VEGFA, and MVD. (A) Western blot analysis of CDC5L expression in PCT and tumor tissues from NSCLC patients. (B) Quantification of CDC5L protein levels in PCT and tumor tissues. (C) IHC staining showing CDC5L expression in PCT and tumor tissues. (D) H-score quantification of CDC5L expression based on IHC staining. Correlation between CDC5L IHC H-score and LINC00323 expression (E), CD31 IHC H-score (F), VEGFA IHC H-score (G), and MVD (H). ***P < 0.001 Expression of CDC5L in NSCLC tissues and its correlation with LINC00323, CD31, VEGFA, and MVD. (A) Western blot analysis of CDC5L expression in PCT and tumor tissues from NSCLC patients. (B) Quantification of CDC5L protein levels in PCT and tumor tissues. (C) IHC staining showing CDC5L expression in PCT and tumor tissues. (D) H-score quantification of CDC5L expression based on IHC staining. Correlation between CDC5L IHC H-score and LINC00323 expression (E), CD31 IHC H-score (F), VEGFA IHC H-score (G), and MVD (H). ***P < 0.001 CDC5L modulates angiogenesis, and MAPK/JAK-STAT pathways in NSCLC and HUVEC cells To verify the role of CDC5L in cell proliferation and angiogenesis, we overexpressed (OE-CDC5L) and knocked down (sh-CDC5L) CDC5L in A549, H358, and HUVEC cells. RT-qPCR analysis confirmed successful modulation of CDC5L expression in these cells (Figs. 9A and Figure S2A). Western blot further validated the changes in CDC5L protein levels following transfection (Figs. 9B and Figure S2B). CCK-8 data revealed that cell viability was increased in CDC5L overexpressing cells relative to controls, while knockdown of CDC5L led to reduced cell viability (Figs. 9C and Figure S2C). EdU assay further confirmed these findings in A549 and H358 cells, showing increased proliferation in the overexpression group and decreased proliferation in the knockdown group (Fig. 9D and E). Then, tube formation assays were conducted using matrigel to assess angiogenesis. The data displayed that CDC5L overexpression in A549 and H358 cells resulted in more extensive tube-like structures, CDC5L knockdown impaired tube formation (Fig. 9F and G, and Figure S2D and S2E). Junction formation also supported these results, with CDC5L overexpression increasing junctions, while the knockdown group showed fewer junctions (Figs. 9H and Figure S2F). Furthermore, CDC5L overexpression improved the integrity of the endothelial barrier, whereas knockdown resulted in reduced TEER values (Figures S2G). Importantly, we also analyzed the MAPK and JAK-STAT pathways by Western blot. The results displayed that CDC5L overexpression in A549, H358, and HUVEC cells enhanced phosphorylation of key proteins in these pathways, including p-JAK1, p-STAT3, p-ERK1/2, and p-p38, while knockdown of CDC5L led to reduced phosphorylation of these proteins (Figure S3). These findings suggest that CDC5L plays a pivotal role in regulating cell proliferation, angiogenesis, endothelial function, MAPK and JAK-STAT pathways in A549, H358, and HUVEC cells. Fig. 9CDC5L modulates cell proliferation and angiogenesis in A549 and H358 cells. (A) RT‒qPCR analysis showing CDC5L expression in A549 and H358 cells after overexpression (OE-CDC5L) or knockdown (sh-CDC5L) of CDC5L. (B) Western blot analysis of CDC5L expression in transfected A549 and H358 cells. (C) The viability of A549 and H358 cells after CDC5L overexpression or knockdown was confirmed via a CCK-8 assay. (D) EdU assay. (E) Quantification of EdU-positive cells. (F) Vascular mimicry formation by A549 and H358 cells in Matrigel to assess the effect of CDC5L overexpression or knockdown. (G) Relative tube length formed by A549 and H358 cells in Matrigel after CDC5L overexpression or knockdown. (H) Relative Nb junctions formed by A549 and H358 cells in the vascular mimicry assay. **P < 0.01, ***P < 0.001 CDC5L modulates cell proliferation and angiogenesis in A549 and H358 cells. (A) RT‒qPCR analysis showing CDC5L expression in A549 and H358 cells after overexpression (OE-CDC5L) or knockdown (sh-CDC5L) of CDC5L. (B) Western blot analysis of CDC5L expression in transfected A549 and H358 cells. (C) The viability of A549 and H358 cells after CDC5L overexpression or knockdown was confirmed via a CCK-8 assay. (D) EdU assay. (E) Quantification of EdU-positive cells. (F) Vascular mimicry formation by A549 and H358 cells in Matrigel to assess the effect of CDC5L overexpression or knockdown. (G) Relative tube length formed by A549 and H358 cells in Matrigel after CDC5L overexpression or knockdown. (H) Relative Nb junctions formed by A549 and H358 cells in the vascular mimicry assay. **P < 0.01, ***P < 0.001 LINC00323 overexpression promotes angiogenesis by regulating CDC5L Subsequently, we further explored the role of LINC00323 in regulating CDC5L and its downstream effects on cell proliferation, angiogenesis, and pathways. Functional complementation experiments were conducted in A549, H358, and HUVEC cells by LINC00323 overexpression and CDC5L knockdown, with successful manipulation of CDC5L expression confirmed by Western blot (Figs. 10A and Figure S4A). CCK-8 data showed that LINC00323 overexpression increased cell viability, while CDC5L knockdown reduced cell viability mediated by LINC00323 overexpression across all cell types (Figs. 10B and Figure S4B). Proliferation was also assessed using EdU assay, with LINC00323 overexpression enhancing proliferation, which also could be reversed by CDC5L knockdown in both A549 and H358 cells (Fig. 10C and D). Then, we found that LINC00323 overexpression facilitated tube formation in Matrigel, while CDC5L knockdown reversed these effects (Figs. 10E and S4C). Quantitative analysis revealed that LINC00323 overexpression promoted the formation of longer tubes and increased junctions, which also could be reduced by CDC5L knockdown in A549, H358, and HUVEC cells (Fig. 10F and G, and Figure S4D and S4E). Further assessment also proved that LINC00323 overexpression improved the integrity of HUVEC monolayers, whereas CDC5L knockdown impaired this integrity, effectively counteracting the positive impact of LINC00323 overexpression (Figure S4F). Additionally, the activation of MAPK and JAK-STAT pathways was examined. LINC00323 overexpression led to enhanced phosphorylation of JAK1, STAT3, ERK1/2, and p38, while CDC5L knockdown decreased the activation of these pathways, indicating that CDC5L knockdown reverses the effects induced by LINC00323 overexpression (Figs. 10H and Figure S4G). Overall, CDC5L knockdown reverses the effects of LINC00323 overexpression, influencing cell proliferation, angiogenesis, endothelial function, and key pathways in A549, H358, and HUVEC cells. Fig. 10Functional complementation of LINC00323 overexpression and CDC5L knockdown in A549 and H358 cells. A549 and H358 cells were transfected with LINC00323 overexpression (OE-323) and CDC5L knockdown (sh-CDC5L) plasmids. (A) Western blot analysis of CDC5L protein expression. (B) Assessment of cell viability via a CCK-8 assay. (C) Representative EdU assay images. (D) Quantification of EdU-positive cells. (E) Representative images depicting tube formation in Matrigel. (F) Measurement of tube length in Matrigel. (G) Junctions. (H) Western blot analysis of MAPK and JAK-STAT pathway proteins. **P < 0.01 vs. the control (CTRL) group; #P < 0.05 vs. the OE-323 group Functional complementation of LINC00323 overexpression and CDC5L knockdown in A549 and H358 cells. A549 and H358 cells were transfected with LINC00323 overexpression (OE-323) and CDC5L knockdown (sh-CDC5L) plasmids. (A) Western blot analysis of CDC5L protein expression. (B) Assessment of cell viability via a CCK-8 assay. (C) Representative EdU assay images. (D) Quantification of EdU-positive cells. (E) Representative images depicting tube formation in Matrigel. (F) Measurement of tube length in Matrigel. (G) Junctions. (H) Western blot analysis of MAPK and JAK-STAT pathway proteins. **P < 0.01 vs. the control (CTRL) group; #P < 0.05 vs. the OE-323 group LINC00323 knockdown attenuates tumor growth and angiogenesis in vivo Besides, we further explored the role of LINC00323 on tumor growth and angiogenesis in vivo. A549 cells with LINC00323 knockdown (LV-sh-323) or control (LV-sh-CTRL) were subcutaneously injected into nude mice. Tumors in the LINC00323 knockdown group were smaller than those in the control group, as measured by tumor volume and weight (Figs. 11A-C). RT-qPCR confirmed efficient knockdown of LINC00323 in the experimental group (Fig. 11D). IHC analysis revealed decreased expression of CDC5L in tumors from the LINC00323 knockdown group (Fig. 11E and F). Additionally, IHC staining for CD31 indicated reduced vascularization in the tumors from the LINC00323 knockdown group (Fig. 11G and H). Cell proliferation, assessed by Ki-67 staining, showed fewer proliferating cells in the LINC00323 knockdown group (Fig. 11I and J). Western blot analysis further revealed decreased CDC5L, p-JAK1, p-STAT3, p-ERK1/2, and p-p38, suggesting a reduction in the activation of these pathways in the LINC00323 knockdown group (Fig. 11K). These findings indicate that LINC00323 knockdown prevents tumor growth, angiogenesis in A549 xenograft models, likely by attenuating MAPK and JAK-STAT pathways. Fig. 11LINC00323 knockdown inhibits tumor growth, angiogenesis, and the MAPK and JAK-STAT pathways in A549 xenograft models. (A) Tumors from A549 xenograft mice treated with LINC00323 knockdown (LV-sh-323) or control (LV-sh-CTRL) vectors after 28 days. (B) Tumor volume measurements at 7, 14, 21, and 28 days. (C) Tumor weights at the end of the study. (D) RT‒qPCR analysis of LINC00323 expression in tumor tissues. (E) IHC staining of CDC5L in tumor tissues from both experimental groups. (F) CDC5L expression from the IHC images. (G) IHC staining of CD31 in tumor tissues, indicating angiogenesis. (H) Quantification of CD31-positive vessels. (I) IHC staining for Ki-67. (J) Quantification of Ki-67-positive cells in tumor tissues. (K) Western blot analysis of MAPK and JAK-STAT pathway proteins in tumor tissues. ***P < 0.001 LINC00323 knockdown inhibits tumor growth, angiogenesis, and the MAPK and JAK-STAT pathways in A549 xenograft models. (A) Tumors from A549 xenograft mice treated with LINC00323 knockdown (LV-sh-323) or control (LV-sh-CTRL) vectors after 28 days. (B) Tumor volume measurements at 7, 14, 21, and 28 days. (C) Tumor weights at the end of the study. (D) RT‒qPCR analysis of LINC00323 expression in tumor tissues. (E) IHC staining of CDC5L in tumor tissues from both experimental groups. (F) CDC5L expression from the IHC images. (G) IHC staining of CD31 in tumor tissues, indicating angiogenesis. (H) Quantification of CD31-positive vessels. (I) IHC staining for Ki-67. (J) Quantification of Ki-67-positive cells in tumor tissues. (K) Western blot analysis of MAPK and JAK-STAT pathway proteins in tumor tissues. ***P < 0.001 CDC5L knockdown weakens tumor growth and angiogenesis in A549 xenograft models Meanwhile, our results testified that CDC5L knockdown in A549 cells (LV-sh-CDC5L) inhibited tumor growth in nude mice, with tumors in the CDC5L knockdown group showing smaller volumes and lower weights than the control group (LV-sh-CTRL) (Figs. 12A–C). Efficient CDC5L knockdown was also confirmed by Western blot and IHC, with reduced expression of CDC5L in the knockdown group (Figs. 12D-F). Besides, IHC staining for CD31 revealed reduced vascularization in tumors from the CDC5L knockdown group (Fig. 12G and H). Cell proliferation, assessed by Ki-67 staining, was also decreased in the CDC5L knockdown group (Fig. 12I and J). Furthermore, p-JAK1, p-STAT3, p-ERK1/2, p-p38 expressions were reduced in tumors from the knockdown group, suggesting that CDC5L regulates the activation of these critical pathways (Fig. 12K). Fig. 12Impact of CDC5L knockdown on tumor growth, angiogenesis, and the MAPK and JAK-STAT pathways in A549 xenograft models. A549 cells were treated with either control (LV-sh-CTRL) or CDC5L-knockdown (LV-sh-CDC5L) lentiviral vectors and subcutaneously injected into nude mice. (A) Tumors from A549 xenografts. (B) Tumor volume measurements at multiple time points. (C) Tumor weight. (D) Western blot analysis of CDC5L protein levels in tumor tissue. (E) IHC analysis of CDC5L expression in tumor sections. (F) Quantification of CDC5L protein expression in tumor samples. (G) IHC staining for CD31 expression. (H) Quantification of CD31 staining. (I) IHC staining for Ki-67 expression. (J) Quantification of Ki-67-positive cells. (K) Western blot analysis. ***P < 0.001 Impact of CDC5L knockdown on tumor growth, angiogenesis, and the MAPK and JAK-STAT pathways in A549 xenograft models. A549 cells were treated with either control (LV-sh-CTRL) or CDC5L-knockdown (LV-sh-CDC5L) lentiviral vectors and subcutaneously injected into nude mice. (A) Tumors from A549 xenografts. (B) Tumor volume measurements at multiple time points. (C) Tumor weight. (D) Western blot analysis of CDC5L protein levels in tumor tissue. (E) IHC analysis of CDC5L expression in tumor sections. (F) Quantification of CDC5L protein expression in tumor samples. (G) IHC staining for CD31 expression. (H) Quantification of CD31 staining. (I) IHC staining for Ki-67 expression. (J) Quantification of Ki-67-positive cells. (K) Western blot analysis. ***P < 0.001 CDC5L overexpression promotes tumor growth, angiogenesis, and MAPK and JAK-STAT pathways mediated by LINC00323 knockdown in A549 xenografts This study further identified the role of CDC5L overexpression in rescuing tumor growth, angiogenesis, MAPK and JAK-STAT pathways in A549 xenografts with LINC00323 knockdown. The LINC00323 knockdown group (LV-sh-323) showed smaller tumors and decreased weight relative to the control group (LV-sh-CTRL), while CDC5L overexpression in the knockdown group (LV-sh-323 + OE-CDC5L) rescued these effects, promoting tumor growth, weight, and volume (Figs. 13A–C). IHC analysis revealed reduced CDC5L expression in the knockdown group, which was restored by CDC5L overexpression (Fig. 13D and E). Angiogenesis, assessed by CD31 staining, was impaired in the knockdown group, while overexpression of CDC5L in the rescue group enhanced vascularization (Fig. 13F and G). Cell proliferation, measured by Ki-67 staining, was markedly lower in the knockdown group, while CDC5L overexpression led to increased proliferation mediated by LINC00323 knockdown (Fig. 13H and I). Western blot analysis revealed decreased p-JAK1, p-STAT3, p-ERK1/2, and p-p38 in the LINC00323 knockdown group, which could be reversed by CDC5L overexpression in the tumor tissues (Fig. 13J). These results suggest that LINC00323 knockdown suppresses tumor growth, angiogenesis, MAPK and JAK-STAT pathways by inhibiting CDC5L in A549 xenografts. Fig. 13CDC5L overexpression rescues tumor growth, angiogenesis, and the MAPK and JAK-STAT pathways in LINC00323-knockdown A549 xenograft models. A549 cells with LINC00323 knockdown (LV-sh-323) or/and CDC5L overexpression (OE-CDC5L) were subcutaneously injected into nude mice. (A) Representative tumor images after 28 days. (B) Tumor volume. (C) Tumor weight. (D) IHC staining for CDC5L. (E) Quantification of CDC5L expression via IHC. (F) IHC staining for CD31. (G) Quantification of CD31 expression. (H) IHC staining for Ki-67. (I) Quantification of Ki-67-positive cells. (J) Western blot analysis. ***P < 0.001 vs. the LV-sh-CTRL group, ##P < 0.01, ###P < 0.001 vs. the LV-sh-323 group CDC5L overexpression rescues tumor growth, angiogenesis, and the MAPK and JAK-STAT pathways in LINC00323-knockdown A549 xenograft models. A549 cells with LINC00323 knockdown (LV-sh-323) or/and CDC5L overexpression (OE-CDC5L) were subcutaneously injected into nude mice. (A) Representative tumor images after 28 days. (B) Tumor volume. (C) Tumor weight. (D) IHC staining for CDC5L. (E) Quantification of CDC5L expression via IHC. (F) IHC staining for CD31. (G) Quantification of CD31 expression. (H) IHC staining for Ki-67. (I) Quantification of Ki-67-positive cells. (J) Western blot analysis. ***P < 0.001 vs. the LV-sh-CTRL group, ##P < 0.01, ###P < 0.001 vs. the LV-sh-323 group Discussion Our study provides valuable insights into the role of LINC00323 in NSCLC progression, particularly its regulation of CDC5L and its effects on angiogenesis. Our data first demonstrated that LINC00323 stabilizes CDC5L, a protein crucial for promoting tumor growth and angiogenesis and maintaining the tumor microenvironment by preventing its degradation [28]. LINC00323 has been shown to be upregulated in several cancers, including breast cancer and GC [10, 29]. In these cancers, its overexpression is linked to poor prognosis and aggressive tumor behavior. However, its specific role in NSCLC remains largely unexplored. Our results reveal that LINC00323 contributes to tumor aggressiveness in NSCLC through the modulation of CDC5L, suggesting that LINC00323 could serve as a potential biomarker and therapeutic target for aggressive NSCLC. Our study revealed that LINC00323 is upregulated in NSCLC tissues, and its overexpression is strongly linked to poor prognosis. This result is consistent with previous findings in GC, where LINC00323 was also found to be overexpressed and associated with aggressive tumor behavior and reduced patient survival [10]. Additionally, our study demonstrated that LINC00323 overexpression enhances cell proliferation in A549 and H358 NSCLC cell lines, reinforcing its role in driving tumor progression. In a related study, LINC00323 knockdown inhibited NSCLC cell proliferation, migration, and tube formation by promoting the degradation of ubiquitinated AKAP1 [30]. In addition, our results extend this understanding by showing that LINC00323 knockdown in A549 xenograft models reduces tumor growth and angiogenesis. These findings provide novel in vivo evidence supporting the role of LINC00323 in promoting NSCLC aggressiveness. Together, our data suggest that LINC00323 plays a pivotal role in NSCLC progression, indicating that it is a potential therapeutic target in the treatment of this malignancy. Angiogenesis, the process of new blood vessel formation, is crucial for tumor growth and metastasis in NSCLC [31, 32]. Markers such as VEGFA and CD31 are associated with poor prognosis [33, 34]. Our study revealed a strong correlation between the upregulation of LINC00323 and the expression of VEGFA, CD31, and MVD in NSCLC tissues. This finding is consistent with those of previous studies, such as those in GC, where LINC00323 was shown to increase VEGFA expression and microvessel density, thereby promoting angiogenesis [10]. Additionally, a prior in vitro study demonstrated that LINC00323 knockdown could prevent tube formation in NSCLC cells by accelerating the degradation of ubiquitinated AKAP1, which aligns with our in vitro findings [30]. Our research also confirmed that LINC00323 can promote the formation of vascular-like structures in NSCLC cells in vitro. Moreover, we found that LINC00323 knockdown could reduce tumor growth and angiogenesis, as evidenced by decreased CD31 expression in A549 xenograft models. These results underscore the critical role of LINC00323 in modulating the tumor microenvironment and promoting angiogenesis in NSCLC. A novel finding of this study is that LINC00323 exerts its effects through exosomal transfer. Exosomes, small extracellular vesicles involved in intercellular communication, carry molecular cargo, including lncRNAs, that influences biological processes [35–37]. We found that exosomal LINC00323 derived from NSCLC cells promoted endothelial cell proliferation and tube formation. These findings suggest that LINC00323 may modulate the TME via exosomes. This finding is consistent with previous studies showing that exosomal lncRNAs, such as MALAT1 and H19, play crucial roles in promoting angiogenesis and cancer metastasis in other tumor types [38, 39]. Our study expands on this concept by demonstrating that LINC00323 transfers regulatory signals to endothelial cells through exosomes, revealing a novel mechanism by which NSCLC tumors communicate with their microenvironment to facilitate vascularization. Our study is the first to confirm that CDC5L is a key regulatory target of LINC00323 in NSCLC, as demonstrated through proteomic analysis and RNA pull-down assays. Additionally, we showed that LINC00323 stabilizes CDC5L by inhibiting its degradation through the ubiquitin‒proteasome pathway. While our experiments demonstrate that LINC00323 stabilizes CDC5L, the precise site-specific mechanism remains to be clarified. It is possible that LINC00323 binds CDC5L in a way that masks ubiquitination sites or interferes with E3 ligase binding, thereby reducing its degradation. Future studies will aim to identify the specific binding sites and relevant E3 ligases. As a critical cell cycle regulator, CDC5L is implicated in the progression of several cancers, including NSCLC [19, 40–42]. Our clinical data revealed that the upregulation of CDC5L is correlated with poor prognosis and angiogenesis markers, which aligns with the findings of previous studies in other cancers, such as GC [42, 43]. Moreover, we found that CDC5L knockdown effectively inhibited NSCLC cell proliferation and angiogenesis, further supporting earlier studies that demonstrated the role of CDC5L in promoting angiogenesis in CRC. In both our in vitro and in vivo experiments, we confirmed that LINC00323-induced stabilization of CDC5L enhances endothelial cell proliferation and tube formation. These findings emphasize the pivotal role of CDC5L in LINC00323-driven angiogenesis in NSCLC. Collectively, our results reveal a novel mechanism by which LINC00323 promotes NSCLC tumor progression through the stabilization of CDC5L. Through proteomic analysis, we revealed that LINC00323 regulates the MAPK/ERK and JAK/STAT pathways, which are crucial in the progression of NSCLC. These pathways play vital roles in key processes, such as cell proliferation, survival, and angiogenesis, all of which contribute to tumor development [44–46]. Previous research has shown that inhibiting the MAPK/ERK pathway can suppress NSCLC growth [47], whereas targeting the JAK/STAT pathway reduces both angiogenesis and tumor growth in preclinical models [48, 49]. Our findings further revealed that LINC00323 regulates these pathways via CDC5L, positioning LINC00323 as a key upstream regulator within the TME. Although both MAPK/ERK and JAK/STAT pathways are activated by LINC00323, it remains unclear whether these pathways are triggered independently or through crosstalk. Future studies could explore potential interactions between these pathways to clarify the precise mechanism. These findings suggest that targeting LINC00323 could serve as an effective therapeutic strategy. Specifically, inhibiting LINC00323 may block both the MAPK/ERK and JAK/STAT pathways simultaneously, providing a dual-target approach to control NSCLC progression. Such a strategy could improve treatment efficacy by targeting the critical pathways involved in tumor growth and vascularization, potentially overcoming resistance to existing therapies. In conclusion, our study reveals that LINC00323 is a novel regulator of CDC5L stability in NSCLC. Through the modulation of CDC5L, LINC00323 activates critical pathways such as the MAPK/ERK and JAK/STAT pathways, promoting angiogenesis and tumor progression (Fig. 14). Additionally, the identification of exosomal transfer as a mechanism by which LINC00323 exerts its effects further enriches our understanding of tumor microenvironment regulation. These findings position LINC00323 as a promising therapeutic target in NSCLC, with potential implications for developing innovative treatment strategies aimed at halting tumor growth, angiogenesis, and metastasis. However, additional research is needed to confirm the clinical relevance of these results, especially in human samples, and to confirm the therapeutic potential of targeting LINC00323 in combination with current therapies. One limitation of this study is the need for further in vivo validation and deeper exploration of the molecular mechanisms of LINC00323, including its potential to overcome therapeutic resistance in NSCLC. Fig. 14Hypothetical graph of the mechanism in this study. Our study reveals that LINC00323 is a novel regulator of CDC5L stability in NSCLC. Through the modulation of CDC5L, LINC00323 activates critical pathways such as the MAPK/ERK and JAK/STAT pathways, promoting angiogenesis and tumor progression Hypothetical graph of the mechanism in this study. Our study reveals that LINC00323 is a novel regulator of CDC5L stability in NSCLC. Through the modulation of CDC5L, LINC00323 activates critical pathways such as the MAPK/ERK and JAK/STAT pathways, promoting angiogenesis and tumor progression Materials and methods Clinical NSCLC samples NSCLC tumor tissues and adjacent noncancerous tissues (PCTs) were obtained from patients who underwent surgery at Zhujiang Hospital of Southern Medical University between March 2016 and December 2018. Informed consent was acquired from all participants before surgery, following the protocols approved by the institutional ethics committee (Approval number: 2024-KY-105-01). The tumor samples were either immediately frozen in liquid nitrogen or fixed in 4% paraformaldehyde (PFA, Sigma). Paired PCT samples were collected from adjacent non-tumor areas and processed similarly. Tumor staging and classification were conducted on the basis of the AJCC Cancer Staging Manual (8th edition). In addition, the correlation between LINC00323 expression and overall survival in NSCLC patients was assessed via Kaplan‒Meier analysis. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Cell culture The human NSCLC cell lines A549 (RRID: CVCL_A549), H358 (RRID: CVCL_1559), HCC827 (RRID: CVCL_2063), H1650 (RRID: CVCL_1483), and BEAS-2B (RRID: CVCL_0168) were obtained from the National Collection of Authenticated Cell Cultures (Shanghai, China), while human umbilical vein endothelial cells (HUVECs) (RRID: CVCL_9Q53) were purchased from Procell (CP-H082, Wuhan, China). A549, H358, HCC827, and H1650 cells were cultured in RPMI-1640 (C11875500BT, Gibco, Beijing, China) supplemented with 10% fetal bovine serum (FBS, 3022 A, Umedium, Anhui. China), 1% penicillin‒streptomycin (BL505A, Biosharp, Hefei, China), and BEAS-2B cells in BEGM (CC-3170, Lonza) supplemented with 0.4% bovine pituitary extract, 0.1 ng/mL epidermal growth factor, 5 µg/mL insulin, and 50 µg/mL hydrocortisone. HUVECs were cultured in HUV-EC-C [HUVEC] Cell Complete Medium (CM-0122, Procell, Wuhan, China). All the cell lines were maintained at 37 °C with 5% CO2. Cell treatment The LINC00323 overexpression construct (OE-323) and shLINC00323 plasmid (sh-323) were purchased from GeneChem (Shanghai, China). CDC5L overexpression and knockdown were conducted via the corresponding lentiviral vectors (OE-CDC5L and sh-CDC5L). The plasmids were transfected into A549, H358, and HUVECs via Lipofectamine 2000 (Thermo Fisher Scientific) according to the manufacturer’s instructions. For functional complementation, LINC00323-overexpressing and CDC5L-knockdown cells were cotransfected into A549, H358, or HUVECs to assess their combined effects. For coculture, A549 cells with LINC00323 overexpression or knockdown were cocultured with HUVECs in 0.4-µm-pore Transwell chambers (Corning). Additionally, LINC00323-silenced A549, H358 and HUVECs were treated with 50 µg/mL cycloheximide (CHX; HY-12320; MedChemExpress, Shanghai, China) for 0, 4, 8, or 12 h or with 10 µM MG132 (HY-13259; MedChemExpress, Shanghai, China) for 8 h. RT‒qPCR Total RNA was extracted from the treated cells and tissues via TRIzol (Invitrogen). The RNA was then reverse transcribed into cDNA via the PrimeScript RT Reagent Kit (Takara Bio, Kyoto, Japan). RT‒qPCR was conducted with SYBR Green Master Mix (Applied Biosystems) and specific primers. The relative level was calculated via the 2−ΔΔCT method. The sequences of primers used are as follows: forward primer for LINC00323: 5’-GGCTGACAGGAGGATGAGTG-3’; downstream primer for LINC00323: 5’-GGTGCGAGTCTGACATTCCA-3’; forward primer for CDC5L: 5’-GTGGCCCAATCGCTGTTACT-3’; downstream primer for CDD5L: 5’-CGGTATTCCTCCATACGCCC-3’; forward primer for GAPDH: 5’-CTCCTCCTGTTCGACAGTCAGC-3’; and downstream primer for GAPDH: 5’-CCCAATACGACCAAATCCGTT-3’. Fluorescence in situ hybridization (FISH) Paraffin-embedded Sects. (4–5 μm) were deparaffinized with xylene and rehydrated with 100%, 95%, 80%, and 70% ethanol. Antigen retrieval was conducted by incubation with 0.01 M citrate buffer (pH 6.0) at 95 °C for 10 min. After cooling, the sections were prehybridized with prehybridization buffer (50% formamide, 2× SSC, 10% nonfat milk, and 1% Tween-20) at 42 °C for 2 h. The LINC00323 RNA probe labeled with a fluorophore (obtained from GENERAL BIOL) was denatured at 37 °C for 10 min and applied to the sections at a concentration of 20 ng/mL. Hybridization was conducted overnight at 42 °C in a humidified chamber. After hybridization, the slides were washed twice with 2× SSC for 5 min. The nuclei were counterstained with 1 µg/mL DAPI for 5 min. The slides were mounted and analyzed via a Leica DM6B fluorescence microscope. Immunohistochemistry (IHC) Paraffin-embedded tumor sections were deparaffinized, rehydrated, and subjected to antigen retrieval by boiling for 20 min. The sections were processed with anti-CDC5L (1:250, Proteintech Cat# 12974-1-AP, RRID: AB_2078510), anti-VEGFA (1:800, Proteintech Cat# 66828-1-Ig, RRID: AB_2882171), anti-CD31 (1:3000, Proteintech Cat# 11265-1-AP, RRID: AB_2299349), and anti-Ki-67 (1:5000, Proteintech Cat# 27309-1-AP, RRID: AB_2756525) antibodies. After incubation with MultirAb™ Polymer HRP-Goat Anti-Rabbit Recombinant Secondary Antibody (1:4000, Proteintech Cat# RGAR011, RRID: AB_3094534) or MultirAb™ Polymer HRP-Goat Anti-Mouse Recombinant Secondary Antibody (1:5000, Proteintech Cat# RGAM011, RRID: AB_3094533), the sections were visualized via the DAB substrate (G1212, Servicebio, Wuhan, China) and counterstained with hematoxylin. The results were evaluated via H-scores and quantified via ImageJ (NIH, Bethesda, MD, USA). Microvessel density (MVD) was quantified by counting CD31-positive microvessels in five randomly selected high-power fields (×400) per section. The average number of microvessels per section was calculated. Counting was performed independently by two observers in a blinded manner to ensure reproducibility. Cell proliferation assay The processed cells (5 × 103 cells/well) were seeded in 96-well plates for 24, 48, and 72 h of incubation. CCK-8 (Dojindo, Kumamoto, Japan) was added, and the absorbance at 450 nm was measured after 3 h. For the EdU assays, the cells were incubated with 10 µM EdU (Sigma‒Aldrich) for 2 h, fixed, and stained with an EdU kit (RiboBio, Guangzhou, China) according to the product specifications. Tube formation assay For the tube formation assays, Matrigel (Corning) was added to 24-well plates and allowed to polymerize at 37 °C for 30 min. HUVECs (1 × 105 cells/well) were then seeded on top and cultured for 12 h. Tube formation was monitored under an Olympus microscope. Tube length and the number of junctions were quantified using ImageJ software. Transepithelial electrical resistance (TEER) measurement The integrity of the endothelial barrier was assessed by TEER measurement via an EVOM2 device (World Precision Instruments). HUVECs were cultured to confluence on 0.4-µm pore Transwell inserts (Corning). TEER values were recorded at specified time intervals using STX2 electrodes, and background resistance from the blank wells was subtracted. The values are expressed as Ω·cm². Exosome isolation The cells were cultured in serum-free medium (HY-K0316, MCE) for 48 h, after which the culture supernatant was collected. Then, the supernatant was first centrifuged at 300 × g for 10 min, followed by a second centrifugation at 2,000 × g for 20 min. The resulting supernatant was then ultracentrifuged at 100,000 × g for 1 h at 4 °C. Exosomes were resuspended in PBS and stored at − 80 °C. Transmission electron microscopy (TEM) Briefly, exosomes were loaded onto carbon-coated copper grids and fixed with 2% paraformaldehyde for 10 min. After fixation, the grids were washed with distilled water and dyed with 2% uranyl acetate for 5 min. The grids were air-dried and visualized via a JEOL JEM-1400 transmission electron microscope (JEOL, Tokyo, Japan). Nanoparticle tracking analysis (NTA) Exosome samples were diluted and analyzed via the NanoSight NS300 system (Malvern, Worcestershire, UK). During analysis, particle motion was tracked to determine particle size and concentration. The data were processed via NTA software. Exosomal uptake Exosomes derived from A549 and H358 cells modified with LINC00323 were labeled with PKH67 Green Fluorescent Dye (Sigma‒Aldrich) as previously described [50]. Briefly, harvested exosomes were suspended in 100 µL of diluent C and combined with 100 µL of PKH67 dye solution (4 × 10− 6 M). Following a 5 min incubation, the labeling reaction was terminated via the addition of serum (200 µL). The labeled exosomes were subsequently rinsed two times with PBS and combined with the appropriate HUVECs for 12 h, and a microscope was used to monitor the uptake of these labeled particles. Western blot Protein was extracted via RIPA buffer (Sigma‒Aldrich) supplemented with protease inhibitors (Roche). Proteins (30 µg) were separated by SDS‒PAGE and transferred to PVDF membranes (Millipore). The membranes were incubated overnight at 4 °C with the following primary antibodies: CDC5L (1:1000, Proteintech Cat# 12974-1-AP, RRID: AB_2078510), phosphorylated JAK1 (p-JAK1) (1:4000, Abcam Cat# ab138005, RRID: AB_3206261), JAK1 (1:3000, Proteintech Cat# 66466-1-Ig, RRID: AB_2881834), phosphorylated STAT3 (p-STAT3) (1:2000, Proteintech Cat# 28945-1-AP, RRID: AB_3206262), STAT3 (1:8000, Proteintech Cat# 10253-2-AP, RRID: AB_2302876), phosphorylated ERK1/2 (p-ERK1/2) (1:2000, Proteintech Cat# 28733-1-AP, RRID: AB_2881202), ERK1/2 (1:6000, Proteintech Cat# 11257-1-AP, RRID: AB_2139822), phosphorylated p38 (p-p38) (1:2000, Proteintech Cat# 28796-1-AP, RRID: AB_2918205), p38 (1:6000, Proteintech Cat# 14064-1-AP, RRID: AB_2878007), and GAPDH (1:200000, Proteintech Cat# 60004-1-Ig, RRID: AB_2107436). After washing, secondary antibodies (Proteintech, Wuhan, China) were applied for 1 h. Protein bands were visualized with enhanced chemiluminescence (ECL) (Thermo Fisher Scientific). For exosomal analysis, the isolated exosomes were processed similarly. The membranes were probed with primary antibodies against exosomal markers, including CD63 (1:4000, Proteintech Cat# 67605-1-Ig, RRID: AB_2882811), CD81 (1:3000, Proteintech Cat# 66866-1-Ig, RRID: AB_2882203), GM130 (1:50000, Proteintech Cat# 11308-1-AP, RRID: AB_2115327), Calnexin (1:20000, Proteintech Cat# 10427-2-AP, RRID: AB_2069033), and CD9 (1:10000, Proteintech Cat# 60232-1-Ig, RRID: AB_11232215). RNA pull-down assay Biotin-labeled LINC00323 sense or antisense RNA probes were used for the RNA pull-down assay. A549, H358, and HUVEC lysates were incubated with RNA probes bound to streptavidin beads (Thermo Fisher Scientific). Bound proteins were identified by mass spectrometry and analyzed by Western blotting after washing. Coimmunoprecipitation (Co-IP) analysis After being lysed and centrifuged at 12,000 × g for 20 min, 2 µg of anti-CDC5L (Abcam) or anti-ubiquitin (Santa Cruz) antibody was added to the supernatant, and the mixture was incubated for 2 h at 4 °C. The immunocomplexes were pulled down with 30 µL of protein A/G agarose beads (Santa Cruz) and incubated for an additional 2 h at 4 °C. After washing, the beads were eluted in SDS and analyzed by Western blotting as described previously. Proteomic analysis Proteins from LINC00323-overexpressing A549, H358, and HUVECs were subjected to either in-solution or in-gel digestion via trypsin (Promega, Madison, WI, USA) following reduction and alkylation steps. The resulting peptides were analyzed via liquid chromatography coupled with tandem mass spectrometry (LC‒MS/MS). The mass spectrometry data were processed via MaxQuant software (version 1.6.10.43), and protein identification was conducted with a stringent false discovery rate (FDR) threshold of < 1%. Differentially expressed proteins (DEPs) were identified, and their patterns were visualized via heatmap analysis. In addition, GSEA was conducted via GSEA software (Broad Institute) to identify enriched pathways. In vivo tumorigenicity assay The effect of the LINC00323/CDCL5 axis on tumorigenesis in vivo was examined in a nude mouse xenograft model. The animal experiments were approved by the ethics committee of Zhujiang Hospital of Southern Medical University (Approval NO. LAEC-2022-130) and were conducted in accordance with the Guide for the Care and Use of Laboratory Animals released by the National Institute of Health (US). A549 cells were infected with lentiviral vectors carrying LINC00323 shRNA (LV-sh-323) or a CDC5L overexpression plasmid (OE-CDC5L). After 48 h, stable cell lines were selected by incubating the cells with puromycin (2 µg/mL) for 2 weeks. The infected cells were then injected subcutaneously into nude mice (6 weeks old). Tumor growth was monitored by counting the tumor volume every 7 days. After 28 days, the tumors were excised, weighed, and subjected to qPCR, Western blotting and IHC. Statistical analysis The data were processed and analyzed with SPSS Statistics (IBM, Armonk, NY, USA), and graphical representations were created via GraphPad Prism 8. Statistical significance was determined through Student’s t test or one-way ANOVA followed by Tukey’s post hoc test. The Pearson correlation coefficient was used to assess relationships between continuous variables. P < 0.05 indicated a significant difference. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1 Supplementary Material 2 Supplementary Material 2